Review Decision (TA241) – January 2016
Review of NICE Technology Appraisal Guidance No. 241; Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
Decision to move the existing guidance to the ‘static list’ – January 2016
The Institute was proposing that the guidance should be moved to the ‘static guidance list’.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
TA241 will now be transferred to the ‘static guidance list’. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
Appendix A - RPP decision paper - January 2016
This page was last updated: